- Home
- TEAM vs RVMD Comparison
TEAM vs RVMD Comparison
Compare TEAM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TEAM | RVMD |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Australia | United States |
| Employees | 13301 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5B | 40.3B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TEAM | RVMD |
|---|---|---|
| Price | $191.61 | $191.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 33 | 25 |
| Target Price | $227.56 | ★ $258.84 |
| AVG Volume (30 Days) | ★ 2.2M | 1.9M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,572,308,000.00 | N/A |
| Revenue This Year | $13.59 | N/A |
| Revenue Next Year | $14.87 | $526.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.02 | N/A |
| 52 Week Low | $56.01 | $56.66 |
| 52 Week High | $229.96 | $224.31 |
Technical Indicators
Market Signals| Indicator | TEAM | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 47.87 |
| Support Level | $167.74 | $188.18 |
| Resistance Level | $199.30 | $194.19 |
| Average True Range (ATR) | 9.60 | 8.20 |
| MACD | -3.05 | 0.44 |
| Stochastic Oscillator | 9.25 | 52.65 |
Price Performance
Historical ComparisonAbout TEAM Atlassian Corporation
Atlassian produces software that helps teams work together more efficiently and more effectively. The company provides project planning and management software, collaboration tools, and service desk solutions. Atlassian was founded in 2002 and is headquartered in Sydney, Australia.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.